share_log

Canaccord Genuity Maintains Buy on AngioDynamics, Lowers Price Target to $17

Canaccord Genuity Maintains Buy on AngioDynamics, Lowers Price Target to $17

Canaccord Genuity 維持對AngioDynamics的買入,將目標價下調至17美元
Benzinga ·  2023/10/05 14:30

Canaccord Genuity analyst William Plovanic maintains AngioDynamics (NASDAQ:ANGO) with a Buy and lowers the price target from $20 to $17.

Canaccel Genuity分析師威廉·普洛瓦尼奇維持AngioDynamic(納斯達克:ANGO)的買入,並將目標價從20美元下調至17美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論